Is Lucid Diagnostics Stock a Good Investment?
Lucid Diagnostics Investment Advice | LUCD |
- Examine Lucid Diagnostics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lucid Diagnostics' leadership team and their track record. Good management can help Lucid Diagnostics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Lucid Diagnostics' business and its evolving consumer preferences.
- Compare Lucid Diagnostics' performance and market position to its competitors. Analyze how Lucid Diagnostics is positioned in terms of product offerings, innovation, and market share.
- Check if Lucid Diagnostics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lucid Diagnostics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lucid Diagnostics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lucid Diagnostics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lucid Diagnostics Stock
Researching Lucid Diagnostics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 59.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.12. Lucid Diagnostics had not issued any dividends in recent years.
To determine if Lucid Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lucid Diagnostics' research are outlined below:
| Lucid Diagnostics has some characteristics of a very speculative penny stock | |
| Lucid Diagnostics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Lucid Diagnostics SWOT analysis stock outlook amid reimbursement progress |
Lucid Diagnostics Quarterly Liabilities And Stockholders Equity |
|
Lucid Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lucid Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lucid Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lucid Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lucid Diagnostics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2022-08-15 | 2022-06-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2022-05-16 | 2022-03-31 | -0.3 | -0.35 | -0.05 | 16 | ||
2023-11-13 | 2023-09-30 | -0.27 | -0.34 | -0.07 | 25 | ||
2023-08-14 | 2023-06-30 | -0.32 | -0.23 | 0.09 | 28 | ||
2022-03-28 | 2021-12-31 | -0.2 | -0.32 | -0.12 | 60 | ||
2024-05-13 | 2024-03-31 | -0.27 | -0.4 | -0.13 | 48 | ||
2023-03-13 | 2022-12-31 | -0.38 | -0.23 | 0.15 | 39 |
Know Lucid Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lucid Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lucid Diagnostics backward and forwards among themselves. Lucid Diagnostics' institutional investor refers to the entity that pools money to purchase Lucid Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 27 K | Tower Research Capital Llc | 2024-06-30 | 19.8 K | Virtu Financial Llc | 2024-06-30 | 14.2 K | Northern Trust Corp | 2024-09-30 | 13.1 K | First Manhattan Co. Llc | 2024-09-30 | 12.6 K | Resources Investment Advisors Inc | 2024-09-30 | 11.2 K | Byrne Asset Management Llc | 2024-06-30 | 11 K | Jones Financial Companies Lllp | 2024-06-30 | 3.8 K | Wells Fargo & Co | 2024-06-30 | 3.5 K | Luminus Management, Llc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 560.9 K |
Lucid Diagnostics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.39 M.Market Cap |
|
Lucid Diagnostics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.04) | (2.14) | |
| Return On Capital Employed | 22.96 | 24.10 | |
| Return On Assets | (1.93) | (2.03) | |
| Return On Equity | 22.79 | 23.93 |
Determining Lucid Diagnostics' profitability involves analyzing its financial statements and using various financial metrics to determine if Lucid Diagnostics is a good buy. For example, gross profit margin measures Lucid Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lucid Diagnostics' profitability and make more informed investment decisions.
Please note, the presentation of Lucid Diagnostics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lucid Diagnostics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lucid Diagnostics' management manipulating its earnings.
Evaluate Lucid Diagnostics' management efficiency
Lucid Diagnostics has return on total asset (ROA) of (1.0102) % which means that it has lost $1.0102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0783) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Lucid Diagnostics' Return On Equity is projected to increase based on the last few years of reporting. At present, Lucid Diagnostics' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.09, whereas Total Assets are forecasted to decline to about 26.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.06) | (0.05) | |
| Tangible Book Value Per Share | (0.09) | (0.08) | |
| Enterprise Value Over EBITDA | (1.11) | (1.05) | |
| Price Book Value Ratio | (25.48) | (26.75) | |
| Enterprise Value Multiple | (1.11) | (1.05) | |
| Price Fair Value | (25.48) | (26.75) | |
| Enterprise Value | 55.2 M | 52.5 M |
Lucid Diagnostics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.416 |
Basic technical analysis of Lucid Stock
As of the 26th of November, Lucid Diagnostics secures the Mean Deviation of 2.21, risk adjusted performance of 0.0846, and Downside Deviation of 2.99. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lucid Diagnostics, as well as the relationship between them. Please verify Lucid Diagnostics coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Lucid Diagnostics is priced some-what accurately, providing market reflects its recent price of 0.98 per share. Given that Lucid Diagnostics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.Lucid Diagnostics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lucid Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lucid Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lucid Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lucid Diagnostics' Outstanding Corporate Bonds
Lucid Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lucid Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lucid bonds can be classified according to their maturity, which is the date when Lucid Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ALUFP 65 15 JAN 28 Corp BondUS549463AC10 | View | |
| Alcatel Lucent USA Corp BondUS549463AE75 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Lucid Diagnostics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lucid Diagnostics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0846 | |||
| Market Risk Adjusted Performance | 1.16 | |||
| Mean Deviation | 2.21 | |||
| Semi Deviation | 2.36 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 991.58 | |||
| Standard Deviation | 2.83 | |||
| Variance | 8.03 | |||
| Information Ratio | 0.0547 | |||
| Jensen Alpha | 0.2468 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0518 | |||
| Treynor Ratio | 1.15 | |||
| Maximum Drawdown | 12.93 | |||
| Value At Risk | (4.04) | |||
| Potential Upside | 5.13 | |||
| Downside Variance | 8.95 | |||
| Semi Variance | 5.59 | |||
| Expected Short fall | (2.72) | |||
| Skewness | 0.2693 | |||
| Kurtosis | (0.07) |
| Risk Adjusted Performance | 0.0846 | |||
| Market Risk Adjusted Performance | 1.16 | |||
| Mean Deviation | 2.21 | |||
| Semi Deviation | 2.36 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 991.58 | |||
| Standard Deviation | 2.83 | |||
| Variance | 8.03 | |||
| Information Ratio | 0.0547 | |||
| Jensen Alpha | 0.2468 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0518 | |||
| Treynor Ratio | 1.15 | |||
| Maximum Drawdown | 12.93 | |||
| Value At Risk | (4.04) | |||
| Potential Upside | 5.13 | |||
| Downside Variance | 8.95 | |||
| Semi Variance | 5.59 | |||
| Expected Short fall | (2.72) | |||
| Skewness | 0.2693 | |||
| Kurtosis | (0.07) |
Consider Lucid Diagnostics' intraday indicators
Lucid Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lucid Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 28783.55 | |||
| Daily Balance Of Power | (0.40) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.98 | |||
| Day Typical Price | 0.98 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 69.19 |
Lucid Stock media impact
Far too much social signal, news, headlines, and media speculation about Lucid Diagnostics that are available to investors today. That information is available publicly through Lucid media outlets and privately through word of mouth or via Lucid internal channels. However, regardless of the origin, that massive amount of Lucid data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lucid Diagnostics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lucid Diagnostics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lucid Diagnostics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lucid Diagnostics alpha.
Lucid Diagnostics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lucid Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lucid Diagnostics Corporate Management
| Michael Gordon | General Secretary | Profile | |
| Lishan MD | Chairman CEO | Profile | |
| Joseph MD | Strategic Cofounder | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Adrian Miller | VP Relations | Profile | |
| Amitabh MD | Strategic Cofounder | Profile | |
| Deepika Lakhani | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lucid Diagnostics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.